Search

Displaying results 1211 - 1220 of 4238 in total
  1. Drug

    Nitroprusside

    go.drugbank.com/drugs/DB00325
    ApprovedInvestigational

    Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles).

  2. Drug

    Arformoterol

    go.drugbank.com/drugs/DB01274
    Approved

    The use of arformoterol is pending revision due to safety concerns in regards to an increased risk of severe exacerbation of asthma symptoms, leading to hospitalization as well as death in some patients

  3. Drug

    Pafolacianine

    go.drugbank.com/drugs/DB15413
    ApprovedInvestigational

    [A242572] On November 29, 2021, the FDA approved pafolacianine as an adjunct imaging agent for intraoperative identification of malignant lesions in adult patients with ovarian cancer.

  4. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.

  5. Drug

    Ichthammol

    go.drugbank.com/drugs/DB11341
    Approved

    It is available in OTC products as an active ingredient for the treatment of skin disorders such as eczema, psoriasis and boils as it is thought to exhibit anti-inflammatory, antibacterial and antimycotic … Ichthammol is also referred to as ammonium bituminosulfonate or ammonium bituminosulphonate.

  6. Drug

    Odesivimab

    go.drugbank.com/drugs/DB15900
    ApprovedInvestigational

    [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions

  7. Drug

    Anifrolumab

    go.drugbank.com/drugs/DB11976
    ApprovedInvestigational

    [A237054] The design of early clinical trials of anti-interferon treatments such as anifrolumab, rontalizumab, and sifalimumab have come under criticism. … [A237079,L34929] Three monoclonal antibodies (anifrolumab, [rontalizumab], and [sifalimumab]) that target the type 1 interferon pathway entered clinical trials as potential treatments for systemic lupus

  8. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin

  9. Drug

    Factor IX Complex (Human)

    go.drugbank.com/drugs/DB11330
    ApprovedInvestigational

    Also known as prothrombin complex concentrate, products containing this complex often include Factor IX (antihemophilic factor B), Factor II (prothrombin), Factor X (Stuart-Prower Factor), and low levels … As the product Kcentra, Factor IX Complex is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients

  10. Drug

    Alclofenac

    go.drugbank.com/drugs/DB13167
    ApprovedWithdrawn

    Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.